For all press and media enquiries please contact mediarelations@chiesi.com
The Board of Directors and the Management Team will ensure leadership continuity in this transitional phase until a new CEO is formally appointed. A new chapter opens at Chiesi as the 11-year tenure of CEO Ugo Di Francesco comes to a close at the end of 2022. The announcement that Chiesi has begun a…
Chiesi Group announces positive results of pharmacokinetic (PK) studies completed in May 2022 on a leading inhaler in development for the treatment of asthma and COPD, formulated with a new low global warming potential propellant. Promising results with the new formulation show a similar profile…
Chiesi’s Annual and Sustainability Report 2021 is released today; Progress towards business, environmental and social targets is strong; Company is joining forces with all stakeholders to advance sustainable healthcare. Parma (Italy) July 14 th, 2022 – Chiesi, the international research-focused…
New investment will progress potential treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure and remodeling in the blood vessels that supply the lungs and can lead to heart failure. Current approved medications mainly address the symptoms of this rare…
Like many around the world, the people at Chiesi are shocked by the ongoing conflict as we witness the distress of all those affected. Chiesi strongly condemns all acts of violence, and we call for a peaceful and immediate resolution of the ongoing conflict in Ukraine. In more than 85 years of our…
PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta. Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102. BLA resubmission planned for the second half of 2022. CARMIEL, Israel and…
Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6% Growth across global markets; China up 22%, US up >10% Continued focus on innovation: Chiesi invests almost 20% of turnover in R&D in 2021 Chiesi recognised as Top Employer in eight global markets and as Top Employer…
New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). The new propellant will reduce the carbon footprint of pMDI inhalers by up to 90%, down to a similar level as a dry powder inhaler (DPI). [1] New inhaler will…
On Monday 17 January, Chiesi had the honour of welcoming the Minister for Territorial Cohesion and Relations with Local Authorities, Ms Jacqueline Gourault, at its industrial site in La Chaussée Saint-Victor. Following the postponement of the Choose France summit due to the health situation, the…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
